Prestara prasterone: Preliminary Phase III data

Preliminary data from the 1-year follow-up, open-label extension trial (GL03-01) of the 6-month, double-blind, placebo-controlled, U.S. and Mexican Phase III GL02-01 trial showed that 200 mg once-dail...